Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426764 · ClinicalTrials.gov registry record · Phase 2
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00426764 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 131 participants.
The verdict
NCT00426764, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.
Interventions
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2007-06-19 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426764
The ClinicalTrials.gov registry entry for NCT00426764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Romidepsin is the first listed.
NCT00426764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426764 about?
NCT00426764 is a clinical study titled "A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma". The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.
What is the current status of trial NCT00426764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2007-06-19. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT00426764?
The interventions under investigation include: Romidepsin (DRUG).
Who is sponsoring clinical trial NCT00426764?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.